Becker Capital Management Inc. Lowers Holdings in McKesson Corporation $MCK

Becker Capital Management Inc. lowered its holdings in McKesson Corporation (NYSE:MCK) by 1.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,395 shares of the company’s stock after selling 1,563 shares during the quarter. McKesson accounts for 1.8% of Becker Capital Management Inc.’s holdings, making the stock its 12th largest holding. Becker Capital Management Inc.’s holdings in McKesson were worth $61,401,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. IAM Advisory LLC lifted its position in McKesson by 0.3% in the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock valued at $3,019,000 after buying an additional 13 shares during the last quarter. PDS Planning Inc raised its stake in shares of McKesson by 1.1% in the 3rd quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock valued at $934,000 after acquiring an additional 13 shares during the period. Berkshire Asset Management LLC PA lifted its holdings in shares of McKesson by 4.6% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after acquiring an additional 13 shares during the last quarter. Goldstein Advisors LLC boosted its position in shares of McKesson by 4.4% during the 3rd quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock worth $258,000 after purchasing an additional 14 shares during the period. Finally, Warren Street Wealth Advisors LLC increased its holdings in McKesson by 4.9% in the 3rd quarter. Warren Street Wealth Advisors LLC now owns 319 shares of the company’s stock valued at $246,000 after purchasing an additional 15 shares during the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the sale, the executive vice president owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Maria Martinez sold 349 shares of McKesson stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the transaction, the director directly owned 301 shares in the company, valued at approximately $282,900.87. This trade represents a 53.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 1,143 shares of company stock worth $1,046,070. 0.08% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on MCK. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Evercore restated an “outperform” rating and set a $1,000.00 target price on shares of McKesson in a report on Thursday, November 6th. Zacks Research lowered shares of McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Wall Street Zen lowered shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $966.00 price target on shares of McKesson in a research report on Thursday, January 29th. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $943.50.

McKesson Trading Up 1.0%

Shares of MCK stock opened at $984.61 on Monday. The company has a market cap of $120.60 billion, a P/E ratio of 28.32, a PEG ratio of 1.59 and a beta of 0.38. The firm has a fifty day moving average price of $868.77 and a 200 day moving average price of $807.56. McKesson Corporation has a 12 month low of $621.88 and a 12 month high of $987.37.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same period in the previous year, the business earned $8.03 EPS. McKesson’s revenue for the quarter was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities analysts forecast that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.